AMENDMENT NO. 1 TO VETO CELL PRODUCTION AND CLINICAL TRIAL PROGRAM AGREEMENTVeto Cell Production and Clinical Trial Program Agreement • May 20th, 2019 • Cell Source, Inc. • Pharmaceutical preparations
This Amendment No. 1 to the Veto Cell Production and Clinical Trial Program Agreement (“Amendment”) is made and entered into as of April 4, 2019 by and between Cell Source Limited (“Cell Source”) and The University of Texas M.D. Anderson Cancer Center (“MD Anderson”), a member institution of The University of Texas System (“System”).
AMENDMENT No. 2 TO VETO CELL PRODUCTION AND CLINICAL TRIAL PROGRAM AGREEMENTVeto Cell Production and Clinical Trial Program Agreement • August 19th, 2024 • Cell Source, Inc. • Pharmaceutical preparations
This Amendment No. 2 to the Veto Cell Production and Clinical Trial Program Agreement (“Amendment”) is made and entered into as of August 7, 2019 by and between Cell Source Limited (“Cell Source”) and The University of Texas M.D. Anderson Cancer Center (“MD Anderson”), a member institution of The University of Texas System (“System”).
AMENDMENT No. 3 TO VETO CELL PRODUCTION AND CLINICAL TRIAL PROGRAM AGREEMENTVeto Cell Production and Clinical Trial Program Agreement • August 19th, 2024 • Cell Source, Inc. • Pharmaceutical preparations
This Amendment No. 3 to the Veto Cell Production and Clinical Trial Program Agreement (“Amendment”) is made and entered into as of May 1, 2023 by and between Cell Source Limited (“Cell Source”) and The University of Texas M.D. Anderson Cancer Center (“MD Anderson”), a member institution of The University of Texas System (“System”).
